Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system
Open accessThe DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
Background: Cancer treatment with a variety of chemotherapeutic agents often is associated with delayed adverse neurological consequences. Despite their clinical importance, almost nothing is known about the basis for such effects. It is not even known whether the occurrence of delayed adverse effects requires exposure to multiple chemotherapeutic agents, the presence of both chemotherapeutic agents and the body's own response to cancer, prolonged damage to the blood-brain barrier, inflammation or other such changes. Nor are there any animal models that could enable the study of this important problem. Results: We found that clinically relevant concentrations of 5-fluorouracil (5-FU; a widely used chemotherapeutic agent) were toxic for both central nervous system (CNS) progenitor cells and non-dividing oligodendrocytes in vitro and in vivo. Short-term systemic administration of 5-FU caused both acute CNS damage and a syndrome of progressively worsening delayed damage to myelinated tracts of the CNS associated with altered transcriptional regulation in oligodendrocytes and extensive myelin pathology. Functional analysis also provided the first demonstration of delayed effects of chemotherapy on the latency of impulse conduction in the auditory system, offering the possibility of non-invasive analysis of myelin damage associated with cancer treatment. Conclusions: Our studies demonstrate that systemic treatment with a single chemotherapeutic agent, 5-FU, is sufficient to cause a syndrome of delayed CNS damage and provide the first animal model of delayed damage to white-matter tracts of individuals treated with systemic chemotherapy. Unlike that caused by local irradiation, the degeneration caused by 5-FU treatment did not correlate with either chronic inflammation or extensive vascular damage and appears to represent a new class of delayed degenerative damage in the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 CNS progenitor cells are vulnerable to clinically relevant levels of 5-FU exposure. (a) A summary of the putative relationships between the different cell types under study (for discussion of this and alternative views on lineage relationships in the CNS, see [199,200]). Pluripotent neuroepithelial stem cells (NSC) give rise to glial restricted precursor (GRP) cells and neuron restricted precursor (NRP) cells. GRP cells in turn give rise to astrocytes and oligodendrocyte-type-2 astrocyte progenitor/oligodendrocyte precursor cells (O-2A/OPCs), the ancestors of oligodendrocytes. (b,c) Primary CNS cells (b) or various cancer cell lines (c) were grown on coverslips and exposed to 5-FU for 24 h before analysis of cell viability as described in Materials and methods. 5-FU concentrations were chosen on the basis of drug concentrations reached in humans after conventional 5-FU treatment. None of the tumor lines tested were sensitive to 5-FU treatment in this dose range, whereas O-2A/OPCs, oligodendrocytes, GRP cells and human umbilical vein endothelial cells (HUVECs) were sensitive. (d,e) Exposure conditions designed to mimic the exposure levels associated with long-term infusion (d) or high-dose bolus administration (e) yielded similar results, with vulnerability of O-2A/OPCs and non-dividing oligodendrocytes to 5-FU exceeding the vulnerability of rapidly dividing cancer cells. As shown in (b,d), the vulnerability of HUVECs also exceeds the vulnerability of cancer cells. Each experiment was carried out in quadruplicate and was repeated at least twice in independent experiments. Data represent mean of survival ± s.e.m, normalized to control values.](https://figures.cochat.ai/paper-figures/1e1e4baf61204ebcbcfb8ba9503ec507/systemic-5-fluorouracil-treatment-causes-a-syndrome-of-delayed-myelin-figure-1.jpg)










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mainstay of CRC treatment, 5‐fluorouracil, has several side effects, including toxicity to both central nervous system progenitor cells and oligodendrocytes, even in the short term, limiting its long‐term clinical use [31, 32].”
From Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models (2024) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–207 of 207
Neu, I. S. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04079.x · Cited by 9
BCG-induced protection against malignant melanoma: Possible immunospecific effect in a murine system
Faraci, R. P., Barone, J., & Schour, L. (1975) · Cancer · doi:10.1002/1097-0142(197502)35:2<469::aid-cncr2820350226>3.0.co;2-r · Cited by 7
Leukoencephalopathy Following Chemotherapy for Colonic Carcinoma
Mak, W., Cheng, C. P.-W., & Cheung, R. T. F. (2001) · Clinical Radiology · doi:10.1053/crad.1999.0278 · Cited by 7
Gastric cancer. treatment of advanced disease and new drugs
Francesco, C. (2005) · Frontiers in bioscience · doi:10.2741/1768 · Cited by 7
Enterline, D. S., Davey, N., & Tien, R. D. (1995) · American Journal of Roentgenology · doi:10.2214/ajr.165.1.7785607 · Cited by 7
Neuroradiology case of the day. Gliomatosis cerebri.
Enterline, D. S., Davey, N., & Tien, R. D. (1995) · American Journal of Roentgenology · doi:10.2214/ajr.165.1.7785606 · Cited by 5
Treatment of advanced disease and new drugs.
Frustaci, S., Buonadonna, A., Mura, N. L., Berretta, M., & Paoli, A. D. (2003) · PubMed · Cited by 3
Research works printed but not linked: 3
- Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007, 103: 303-311. 10.1007/s10549-006-9380-z. · DOI · Paper page
- Raimondi AJ, Tomita T: Advantages of 'total' resection of medulloblastoma and disadvantages of full head postoperative radiation therapy. Childs Brain. 1979, 5: 550-551.
- Cankaya H, Oner AF, Egeli E, Caksen H, Uner A, Akcay G: Auditory brainstem response in children with iron deficiency anemia. Acta Paediatr Taiwan. 2003, 44: 21-24.
Cited by
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70294-1 · Cited by 998
Prevalence, mechanisms, and management of cancer-related cognitive impairment
Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.864260 · Cited by 745
Wefel, J. S., Kesler, S. R., Noll, K. R., & Schagen, S. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21258 · Cited by 532
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer
Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010) · Cancer · doi:10.1002/cncr.25098 · Cited by 513
Oxidative Stress and Neurodegenerative Disorders
Li, J., O, W., Li, W., Jiang, Z.-G., & Ghanbari, H. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224438 · Cited by 504
Metadata
- Authors
- Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Pröschel, M., & Noble, M.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Noble, Mark
- Venue
- Journal of Biology
- Published
- 2008-04-22
- Volume
- 7
- Issue
- 4
- Pages
- 12-12
- ISSN
- 1475-4924 (ISSN-L)
- PMC
- PMC2397490
- OpenAlex
- W2152709121
- Cited by
- 316
- References
- 203
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 8 · 2023: 10 · 2022: 21 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 14 · 2016: 25 · 2015: 16 · 2014: 26 · 2013: 25 · 2012: 18
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Journal of Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute on Deafness and Other Communication Disorders (R01DC003086)
- National Institute of Neurological Disorders and Stroke (R01NS044701, NS44701)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD39702, R01HD039702)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- 5-fluorouracil, chemotherapy-induced neurotoxicity, white matter degeneration, myelin pathology, transcriptional regulation, auditory system, central nervous system
- MeSH terms
- Action Potentials, Animals, Antineoplastic Agents, Auditory Pathways, Bromodeoxyuridine, Central Nervous System, Fluorouracil, Humans, Indoles, Microscopy, Fluorescence, Myelin Sheath, Stem Cells, Tetrazolium Salts, Thiazoles, In Situ Nick-End Labeling, Cell Line, Tumor, Microscopy, Electron, Transmission, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.